Sugi Predict

Sugi Predict / Compounds / SCHEMBL2182127

SCHEMBL2182127

SCHEMBL2182127

CCC(CC)c1cc(C)nc2c(-c3sc(N4CCOCC4)nc3Cl)c(C)nn12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRHR1 P34998 2/20 0.61
▸ CRHR2 Q13324 1/20 0.61
▸ KMT2A Q03164 3/20 0.46
▸ POLB P06746 1/20 0.46
▸ HSD17B10 Q99714 4/20 0.45
▸ LMNA P02545 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ USP2 O75604 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ RAB9A P51151 3/20 0.36
▸ NPY1R P25929 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ NPC1 O15118 2/20 0.35
▸ PIK3CD O00329 1/20 0.35
▸ PIK3CA P42336 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29430976 0.95 CRHR1 (0.57) CRHR1CRHR2KMT2APOLBHSD17B10
SCHEMBL2180543 0.93 CRHR1 (0.54) CRHR1CRHR2KMT2APOLBHSD17B10
SCHEMBL22958804 0.93 CRHR1 (0.56) CRHR1CRHR2KMT2APOLBHSD17B10
SCHEMBL2931339 0.91 CRHR1 (0.52) CRHR1CRHR2KMT2APOLBHSD17B10
SCHEMBL25490371 0.91 CRHR1 (0.56) CRHR1CRHR2KMT2APOLBHSD17B10
SCHEMBL25490375 0.90 CRHR1 (0.49) CRHR1CRHR2KMT2APOLBHSD17B10
SCHEMBL2496095 0.89 CRHR1 (0.49) CRHR1CRHR2KMT2APOLBHSD17B10
SCHEMBL26241741 0.88 CRHR1 (0.47) CRHR1CRHR2KMT2APOLBHSD17B10
SCHEMBL2494849 0.87 CRHR1 (0.48) CRHR1CRHR2KMT2APOLBHSD17B10
Tildacerfont SCHEMBL29462437 0.87 CRHR1 (0.49) CRHR1CRHR2KMT2APOLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4656192-A2 TILDACERFONT AND DERIVATIVES THEREOF FOR TREATING POLYCYSTIC OVARY SYNDROME Spruce Biosciences, Inc. (US) 2025-12-03 — — EP claimed
US-20240293421-A1 CRYSTALLINE COMPOSITION OF TILDACERFONT AND METHODS OF USE AND PREPARATION THEREOF AVENUE CAPITAL MANAGEMENT II, L.P. 2024-09-05 — — US claimed
CN-118574833-A TILDACERFONT crystalline compositions and methods of use and preparation thereof 云杉生物科学公司 2024-08-30 — — CN claimed
CN-116322544-B Methods and compositions for treating polycystic ovary syndrome 云杉生物科学公司 2024-08-02 — — CN claimed
EP-4402142-A1 CRYSTALLINE COMPOSITION OF TILDACERFONT AND METHODS OF USE AND PREPARATION THEREOF Spruce Biosciences, Inc. (US) 2024-07-24 — — EP claimed
CN-116322544-A Methods and compositions for treating polycystic ovary syndrome 云杉生物科学公司 2023-06-23 — — CN claimed
WO-2023091684-A1 CRYSTALLINE COMPOSITION OF TILDACERFONT AND METHODS OF USE AND PREPARATION THEREOF SPRUCE BIOSCIENCES, INC. (US) 2023-05-25 — — WO claimed
US-20200255436-A1 CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS AVENUE CAPITAL MANAGEMENT II, L.P. 2020-08-13 — — US claimed
US-8030304-B2 Thiazole pyrazolopyrimidines CRF1 receptor antagonists ELI LILLY AND COMPANY (US) 2011-10-04 — — US claimed
EP-2094709-B1 THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2010-09-15 — — EP claimed
US-20100222339-A1 Thiazole pyrazolopyrimidines CRF1 receptor antagonists ELI LILLY AND COMPANY 2010-09-02 — — US claimed
EP-4656192-A2 TILDACERFONT AND DERIVATIVES THEREOF FOR TREATING POLYCYSTIC OVARY SYNDROME Spruce Biosciences, Inc. (US) 2025-12-03 — — EP disclosed
US-20250206733-A1 METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME AVENUE CAPITAL MANAGEMENT II, L.P. 2025-06-26 — — US disclosed
CN-118948857-A Methods and compositions for treating polycystic ovary syndrome 云杉生物科学公司 2024-11-15 — — CN disclosed
CN-118845788-A Corticotropin releasing factor receptor antagonists 云杉生物科学公司 2024-10-29 — — CN disclosed
US-20100222339-A1 Thiazole pyrazolopyrimidines CRF1 receptor antagonists ELI LILLY AND COMPANY 2010-09-02 — — US disclosed
US-20100222339-A1 Thiazole pyrazolopyrimidines CRF1 receptor antagonists ELI LILLY AND COMPANY 2010-09-02 — — US disclosed
WO-2010039678-A1 THIAZOLYL-PYRAZOLOPYRIMIDINE COMPOUNDS AS SYNTHETIC INTERMEDIATES AND RELATED SYNTHETIC PROCESSES ELI LILLY AND COMPANY (US) 2010-04-08 — — WO disclosed
WO-2010039678-A1 THIAZOLYL-PYRAZOLOPYRIMIDINE COMPOUNDS AS SYNTHETIC INTERMEDIATES AND RELATED SYNTHETIC PROCESSES ELI LILLY AND COMPANY (US) 2010-04-08 — — WO disclosed
WO-2008036579-A1 THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2008-03-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206733-A1 METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME CYP17A1, SHBG, NR5A1 CRHR1 158/4885CRHR2 239/4885KMT2A 1639/4885
US-20100222339-A1 Thiazole pyrazolopyrimidines CRF1 receptor antagonists CRHR1, CRH, CRHR2 CRHR1 1/4885CRHR2 3/4885KMT2A 3957/4885
US-20240293421-A1 CRYSTALLINE COMPOSITION OF TILDACERFONT AND METHODS OF USE AND PREPARATION THEREOF CRH, CRHR1, MC2R CRHR1 2/4885CRHR2 4/4885KMT2A 4768/4885
US-20200255436-A1 CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS CRH, CRHR2, CRHR1 CRHR1 3/4885CRHR2 2/4885KMT2A 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.